Agilent Technologies, Inc. (NYSE:A) Holdings Lowered by Boston Common Asset Management LLC

by · The Cerbat Gem

Boston Common Asset Management LLC trimmed its stake in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) by 53.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,725 shares of the medical research company’s stock after selling 67,223 shares during the period. Boston Common Asset Management LLC’s holdings in Agilent Technologies were worth $8,719,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Livelsberger Financial Advisory acquired a new position in Agilent Technologies during the fourth quarter valued at $26,000. Crewe Advisors LLC increased its holdings in shares of Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 101 shares during the last quarter. Ridgewood Investments LLC acquired a new position in shares of Agilent Technologies during the 2nd quarter valued at about $29,000. Rise Advisors LLC boosted its stake in Agilent Technologies by 527.8% during the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 190 shares during the period. Finally, Riverview Trust Co bought a new stake in Agilent Technologies during the 1st quarter valued at approximately $41,000. 87.42% of the stock is owned by hedge funds and other institutional investors.

Agilent Technologies Stock Down 1.4 %

NYSE A opened at $142.76 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The stock has a market capitalization of $41.65 billion, a P/E ratio of 33.75, a price-to-earnings-growth ratio of 6.48 and a beta of 1.05. The stock has a fifty day moving average of $140.42 and a 200-day moving average of $138.96. Agilent Technologies, Inc. has a 52 week low of $96.80 and a 52 week high of $155.35.

Agilent Technologies (NYSE:A – Get Free Report) last released its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the prior year, the company posted $1.43 earnings per share. Agilent Technologies’s revenue was down 5.6% on a year-over-year basis. On average, equities research analysts forecast that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st will be issued a dividend of $0.236 per share. The ex-dividend date is Tuesday, October 1st. This represents a $0.94 annualized dividend and a yield of 0.66%. Agilent Technologies’s payout ratio is presently 22.22%.

Insider Buying and Selling

In other news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $140.00, for a total transaction of $274,120.00. Following the sale, the chief executive officer now owns 26,076 shares of the company’s stock, valued at $3,650,640. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,953 shares of company stock worth $2,013,630. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on A. Wolfe Research downgraded Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. Bank of America raised their price objective on Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Evercore ISI raised their price objective on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Stifel Nicolaus restated a “buy” rating and set a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. Finally, Wells Fargo & Company assumed coverage on Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 target price for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Agilent Technologies has an average rating of “Moderate Buy” and a consensus target price of $143.64.

View Our Latest Research Report on A

About Agilent Technologies

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Articles

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).